ðã®ã·ããšããŒã
protocol=æé çã ã®æå³ã
ãã®68.69ããŒãžâ
翻蚳:
PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) Protocol C4591001 ç·æ§ã®å®¶æãŸãã¯å»çåŸäºè
ããåžå
¥ãŸãã¯ç®èæ¥è§Šã«ããè©Šéšä»å
¥ã«ãããããåŸãåŠåš åãŸãã¯åŠåš ååŸã«ããŒãããŒã®å¥³æ§ãæŽé²ããå Žåãæ²»éšè²¬ä»»è
ã¯ãSAEãçºçãããã©ããã«ããããããæ²»éšè²¬ä»»è
ãæ°ä»ããæç¹ãã24æé以å
ã«EDPããã¡ã€ã¶ãŒå®å
šæ§ã»ã³ã¿ãŒã«å ±åããªããã°ãªããŸãããæåã«æåºããæ
å ±ã«ã¯ãåºç£äºå®æ¥ãå«ããå¿
èŠããããŸãïŒåŠåš ã®çµäºã«é¢é£ããæ
å ±ã«ã€ããŠã¯ä»¥äžãåç
§ïŒãåå è
ãŸãã¯åå è
ã®ããŒãããŒã«EDPãçºçããå ŽåãSAEãçºçãããã©ããã«ããããããæ²»éšè²¬ä»»è
ã¯ãã®æ
å ±ãã¯ã¯ãã³SAEå ±åæžããã³EDPè£è¶³å ±åæžã«èšèŒããŠãã¡ã€ã¶ãŒå®å
šæ§ã«å ±åããªããã°ãªããŸãããåŠåš ã®è©³çŽ°ã¯ïŒè©Šéšä»å
¥ã®éå§åŸïŒè©Šéšä»å
¥ã®æçµæäžãã6ãæåŸãŸã§ã«åéããããç°å¢ãžã®æé²ã«ããEDPãçºçããå Žåãæ²»éšè²¬ä»»å»åž«ã¯ã¯ã¯ãã³SAEå ±åæžããã³EDPè£è¶³æžåŒãçšããŠãã¡ã€ã¶ãŒå®å
šæ§éšã«æ
å ±ãå ±åããå¿
èŠããããŸããæé²æ
å ±ã¯è©Šéšã«ç»é²ãããåå è
ã«ã¯é¢ä¿ããªããããCRFã«ã¯èšé²ãããªãããèšå
¥æžã¿ã®ã¯ã¯ãã³SAEå ±åæžã®ã³ããŒã¯æ²»éšè²¬ä»»å»åž«ã®ãµã€ããã¡ã€ã«ã«ä¿ç®¡ããããçµæãäžæã®EDPå ±åã«ã€ããŠã¯ãåŠåš ãšãã®çµæã«é¢ããäžè¬çãªæ
å ±ãåŸãããã«ãã©ããŒã¢ãããå®æœãããæ²»éšè²¬ä»»å»åž«ã¯ãåŠåš ãå®äºãããŸã§ïŒãŸãã¯åŠåš ãçµäºãããŸã§ïŒè¿œè·¡èª¿æ»ãè¡ããæåã®EDPè£è¶³ãã©ãŒã ã®ãã©ããŒã¢ãããšããŠãçµæããã¡ã€ã¶ãŒå®å
šæ§ã«éç¥ããŸããåºçããå Žåã¯ãæ°çå
ã®æ§é çå®å
šæ§ãåºçæã«è©äŸ¡ããããšãã§ãããåŠåš çµäºã®å Žåã¯ãçµäºã®çç±ãæèšããèšåºçã«å¯èœã§ããã°ãçµäºããèå
ã®æ§é çå®å
šæ§ãèçŒã§è©äŸ¡ãã¹ãã§ããïŒãã ããåŠçœ®åã®æ€æ»çµæãå
倩æ§ç°åžžã®æ±ºå®çãªãã®ã§ããããã®çµæãå ±åãããå Žåãé€ãïŒãåŠåš ã®ç°åžžãªçµæã¯SAESãšã¿ãªããããåŠåš ã®çµæãSAEã®åºæºïŒåå®®å€åŠåš ãèªç¶æµç£ãåå®®å
èå
æ»äº¡ãæ°çå
æ»äº¡ãå
倩æ§ç°åžžãªã©ïŒãæºããå Žåãæ²»éšè²¬ä»»å»åž«ã¯SAESå ±åã®æé ã«åŸãã¹ãã§ãããSAESãšããŠãã¡ã€ã¶ãŒã»ã»ãŒããã£ç€Ÿã«å ±åãããåŠåš çµæã«é¢ããè¿œå æ
å ±ã¯ä»¥äžã®éãã§ããèªç¶æµç£ïŒæµç£ããã³é誀æµç£ãå«ãïŒïŒçåŸ1ãµæ以å
ã«çºçããæ°çå
æ»äº¡ã¯ãå æé¢ä¿ãèæ
®ããã«SAESãšããŠå ±åãããã¹ãã§ããããŸããçåŸ1ã¶æ以éã®ä¹³å
æ»äº¡ã¯ãæ²»éšè²¬ä»»å»åž«ãä¹³å
æ»äº¡ãè©Šéšä»å
¥ãžã®æé²ã«é¢é£ããããŸãã¯é¢é£ããå¯èœæ§ããããšè©äŸ¡ããå ŽåãSAESãšããŠå ±åããã¹ãã§ããã68ããŒãž
PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) Protocol C4591001 EDPã«é¢ããè¿œå æ
å ±ã¯ã¹ãã³ãµãŒããèŠæ±ãããããšããããåºçæ瞟ã®ãããªããã©ããŒã¢ããã¯ã±ãŒã¹ãã€ã±ãŒã¹ã§å¯Ÿå¿ããïŒäŸïŒæ©ç£å
ã®ãã©ããŒã¢ããã§çºéã®é
ãã確èªããïŒãç¶èŠªã被æããå Žåãæ²»éšè²¬ä»»è
ã¯åå è
ã«ãåŠåš äžã®ããŒãããŒãžã®æ
å ±æäŸæžããæž¡ããããŒãããŒã«æž¡ããŠããããæ²»éšè²¬ä»»è
ã¯ãåå è
ãããŒãããŒã«æž¡ãããã«åŠåš äžã®ããŒãããŒã®æ
å ±æäŸæžãæž¡ãããããšãåè³æã«èšé²ããªããã°ãªããªãã8.3.5.2. æ¯ä¹³è²å
äžã®æé² ä»¥äžã®å Žåãæ¯ä¹³è²å
äžã®æé²ãçºçããã女æ§åå è
ãç 究ä»å
¥ãåããŠããéãŸãã¯äžæ¢ããåŸã«æä¹³ããŠããããšãå€æããå Žåã女æ§ãè©Šéšä»å
¥ïŒããªãã¡ãç°å¢æé²ïŒã«æãããŠããããæãããåŸã«æä¹³ããŠããããšãå€æããå Žåãæä¹³äžã®ç°å¢æé²ã®äŸãšããŠã¯ã女æ§ã®å®¶æãŸãã¯å»çåŸäºè
ããåžå
¥ãŸãã¯ç®èæ¥è§Šã«ããè©Šéšä»å
¥ã«æé²ããåŸã«æä¹³ããŠãããšå ±åããå Žåãæãããããæ²»éšè²¬ä»»è
ã¯ãSAEãçºçãããã©ããã«ããããããæ²»éšè²¬ä»»è
ãæ°ä»ããŠãã24æé以å
ã«ãã¡ã€ã¶ãŒå®å
šæ§éšã«æä¹³äžã®æŽé²ãå ±åããªããã°ãªããŸããããã®æ
å ±ã¯ãã¯ã¯ãã³SAEå ±åæžã䜿çšããŠå ±åããå¿
èŠããããŸããæä¹³äžã®æé²ãç°å¢æé²ã®ç¶æ³äžã§çºçããå Žåãæé²æ
å ±ã¯ç 究ã«ç»é²ããåå è
ã«ã¯é¢ä¿ããªãããããã®æ
å ±ã¯CRFã«ã¯èšé²ãããŸããããã ããèšå
¥æžã¿ã®ã¯ã¯ãã³ SAE å ±åæžã®ã³ããŒã¯æ²»éšè²¬ä»»å»åž«ã®ãµã€ããã¡ã€ã«ã«ä¿ç®¡ããããæ¯ä¹³è²å
äžã®å¥³æ§ãžã®äœ¿çšãç¹å¥ã«æ¿èªããããã¡ã€ã¶ãŒç€Ÿã®å»è¬åïŒãã¿ãã³å€ãªã©ïŒããæ¿èªããã䜿çšæ¹æ³ã«åŸã£ãŠæäžãããå Žåãæä¹³äžã®æé²å ±åæžã¯äœæãããŸããããã ããä¹³å
ããã®ãããªè¬å€ã«é¢é£ãã SAE ãçµéšããå Žåããã® SAE ã¯æä¹³äžã®æé²ãšäžç·ã«å ±åãããã8.3.5.3. è·æ¥äžã®æé² è·æ¥äžã®æé²ã¯ããã人ãè©Šéšä»å
¥çã«äºå®å€ã®çŽæ¥æ¥è§Šãããå Žåã«çºçããããã AE ã®çºçã«ã€ãª ãããã©ããã¯ããããªãããã®ãããªäººã«ã¯ãå»çåŸäºè
ã家æãåã³æ²»éšåå è
ã®ã±ã¢ã«é¢äžãããã®ä»ã®åœ¹å²ãå«ãŸãããæ²»éšè²¬ä»»è
ã¯ãé¢é£ããSAEã®æç¡ã«ããããããæ²»éšè²¬ä»»è
ãæ°ä»ããŠãã24æé以å
ã«ãã¡ã€ã¶ãŒã»ã»ãŒããã£ã«è·æ¥äžã®æŽé²ãå ±åããªããã°ãªããŸããããã®æ
å ±ã¯ãã¯ã¯ãã³SAEå ±åæžãçšããŠå ±åããå¿
èŠããããŸãããã ããèšå
¥æžã¿ã®ã¯ã¯ãã³SAEå ±åæžã®ã³ããŒã¯æ²»éšè²¬ä»»å»åž«ã®ãµã€ããã¡ã€ã«ã«ä¿ç®¡ãããŸãã69 ããŒãž
ãã£ããèšãã°
æ ã¡ãæ¥çš®è
ã®åŒæ°ããŸãã¯æ¥çš®è
ãžã®æ¥è§Šã§
æŽé²=被害ãåºãå Žåããããšããããšã
åŠå©Šã«ã€ããŠè§ŠããŠããç¹ã§æµç£ã®ãªã¹ã¯çã
ãããäºã瀺åããŠããããã«æããŸããªãã
æ¥çš®è ã®ã¿ãªãããæªæ¥çš®è ãå±ãªããã
Vt.DãVt.CãæŸèè¶ãäºéãã±ã«ã»ãã³ã
éæ¹ãã¯ãšã³é
žãã¬ã¡ãŸãŒãçã§
æªæ¥çš®è
ã¯èªå·±é²è¡ããŸãããã
ãã®èšäºãæ°ã«å ¥ã£ãããµããŒããããŠã¿ãŸãããïŒ